The Role and Use of Point of Care Testing Devices

Point-of-care testing devices run diagnostic tests right where the patient is, whether that is a busy emergency department, a rural clinic with no nearby laboratory, or someone’s kitchen table. The core advantage is speed: results that a central laboratory might return in hours can appear in minutes, letting clinicians make treatment decisions faster and letting patients spend less time waiting. In emergency departments, discharge times for patients sent home have been shortened by roughly an hour when point-of-care panels replaced standard lab workflows. But faster does not always mean better, and the story of these devices involves real trade-offs between convenience, accuracy, cost, and even environmental impact.

What Counts as a Point-of-Care Test

The category is broad. A home pregnancy test is a point-of-care device. So is a blood glucose meter, a rapid strep swab at a pediatrician’s office, and a portable blood gas analyzer in an intensive care unit. What unites them is that testing happens near or at the site of patient care, rather than requiring a sample to be transported to a centralized laboratory. Some are simple lateral-flow strips that rely on capillary action to draw a fluid sample across a membrane, producing a visible line when the target substance is present. Others are handheld electrochemical sensors, miniaturized versions of the same chemistry that drives full-sized lab instruments. The spectrum runs from a two-dollar malaria test strip used in sub-Saharan Africa to a multi-thousand-dollar tabletop analyzer sitting in an emergency department.

The technology behind the simplest and most widespread devices, lateral-flow assays, is straightforward in concept. A liquid sample moves through zones on a polymer strip by capillary action alone, encountering antibodies attached to colored or fluorescent particles. If the target molecule is present, it binds to those antibodies and gets carried to a detection zone, where a visible line appears. A control line confirms the test ran correctly. No electricity, no moving parts, no training beyond reading the instructions.

More advanced devices push beyond that simplicity. Electrochemical biosensors convert a biological recognition event into a measurable electrical signal, enabling portable instruments that give numerical readouts rather than simple yes-or-no lines. The glucose meter is the most commercially successful example of this approach, and its success has driven enormous research investment into applying similar electrochemical principles to other targets. Newer electrochemical lateral-flow platforms combine the ease of a strip test with digital, quantitative results, bridging the gap between the cheapest rapid tests and full laboratory analyzers.

Where Speed Matters Most

Emergency departments are one of the settings where point-of-care testing has had the clearest impact. A Finnish study comparing a comprehensive point-of-care test panel against conventional laboratory processing found that patients discharged home left roughly 55 minutes faster when no imaging was needed, and about an hour and 22 minutes faster when imaging was also required. Even blood sampling itself happened 19 minutes sooner in the point-of-care group, because staff could draw and analyze blood at the bedside without waiting for a phlebotomist or a lab queue.

A large randomized controlled trial in the UK found more modest gains. Mean time to a disposition decision was about 7.6% shorter with point-of-care testing compared to standard lab work, and the benefit was most pronounced when senior clinicians were involved, with a 19% reduction in decision time and nearly 16% shorter overall stays. The per-test cost was about $12 higher for the point-of-care group, translating to roughly $113 per hour of decision time saved.

⁴

Interestingly, time savings are not universal across all patient groups even within the same department. The Finnish study found no significant reduction in sampling time or length of stay among patients who were admitted to the hospital rather than discharged. This makes sense: admitted patients wait for beds, specialist consultations, and other bottlenecks that have nothing to do with how fast their lab results come back.

Heart Attacks and Sepsis at the Bedside

Two of the most time-critical uses of point-of-care devices in acute care involve ruling out heart attacks and detecting sepsis early. For chest pain, hospitals increasingly use high-sensitivity cardiac troponin assays, proteins released when heart muscle is damaged. A study of over 1,200 patients found that a point-of-care high-sensitivity troponin test performed comparably to the best central laboratory assays for diagnosing heart attacks. A single measurement below a very low threshold at presentation identified 45% of patients as low-risk with a negative predictive value of 100%, meaning none of those patients turned out to have a heart attack. A rapid rule-out algorithm using measurements at presentation and one hour later safely cleared 55% of patients.

⁵

Despite that diagnostic accuracy, translating faster results into faster discharges is not guaranteed. A separate randomized trial found that implementing point-of-care high-sensitivity troponin testing with a similar rapid algorithm did not produce a clinically meaningful reduction in overall emergency department stay.

⁶

The gap between a fast lab result and a fast discharge is filled with human decisions, consultations, documentation, and risk aversion. This is a recurring theme with point-of-care testing: the technology can deliver results in minutes, but the downstream workflow often absorbs much of that time advantage.

For sepsis, point-of-care lactate measurement has shown more consistently positive effects on outcomes rather than just efficiency. A systematic review found that five studies showed a trend toward reduced mortality when lactate was tested at the point of care, with three reaching statistical significance. Two studies also demonstrated faster delivery of antibiotics and intravenous fluids.

⁷

A community hospital that implemented point-of-care blood gas testing saw lactate testing compliance rise from 61% to 91%, and monthly sepsis mortality dropped from about 42% to 8% over the evaluation period.

⁸

That dramatic mortality improvement reflects something important: when a test is easier to do, it gets done more often. And for sepsis, where every hour of delayed treatment worsens survival, simply getting the test done at all can matter more than whether it is done in five minutes versus thirty.

Living with Chronic Disease

Point-of-care testing probably touches the most lives through chronic disease management, particularly diabetes and anticoagulation therapy. The glucose meter is the original point-of-care success story, and the technology has evolved significantly. Continuous glucose monitors, which use a small sensor under the skin to track glucose levels around the clock, represent the latest generation. A randomized trial of people with type 1 diabetes found that those using intermittently scanned continuous glucose monitors had their average blood sugar level drop by an additional half a percentage point compared to the usual-care group at 24 weeks. They also spent about two extra hours per day in their target glucose range and 43 fewer minutes per day in dangerously low blood sugar territory.

⁹

A study of veterans switching from fingerstick monitoring to continuous glucose monitoring found that the change was associated with a drop of nearly one full percentage point in average blood sugar levels.

¹⁰

These numbers translate into real reductions in long-term complications like nerve damage, kidney disease, and vision loss.

Beyond glucose, point-of-care hemoglobin A1c testing in primary care clinics has a practical benefit that goes beyond convenience: it catches people at the moment they are actually in front of a doctor. Practices with point-of-care A1c devices were nearly four times less likely to miss testing at a visit compared to practices that relied on central labs. About a quarter of tested patients had worsening diabetes, and nearly half of those in the point-of-care group were identified during the visit itself rather than days later when a lab result came back.

¹¹

For people taking blood-thinning medications like warfarin, point-of-care INR monitors let patients test at home and adjust their dosing accordingly. Self-testing has been associated with spending about 6 to 7 percentage points more time in the safe therapeutic range compared to standard clinic monitoring.

¹²

Reducing Unnecessary Antibiotics

One of the more surprising applications of point-of-care testing has nothing to do with diagnosing the patient’s actual illness. C-reactive protein, a marker of inflammation, can be measured at the bedside to help a doctor distinguish a likely bacterial infection from a viral one. When someone comes in with a cough or sore throat, the temptation to prescribe antibiotics “just in case” is strong. A point-of-care CRP test gives the doctor a concrete number to anchor that decision.

A meta-analysis of randomized controlled trials found that CRP point-of-care testing reduced immediate antibiotic prescribing for respiratory infections by about 21%, with one unnecessary prescription avoided for every eight patients tested. The trade-off was a modest increase in patients returning for a follow-up visit within 30 days, with about one additional re-consultation for every 27 patients. Clinical recovery and hospital admission rates were no different between the tested and untested groups, suggesting that withholding antibiotics in those cases did not harm patients.

¹³

An earlier meta-analysis reported a similar magnitude of effect, with a 25% reduction in prescribing at the initial visit.

¹⁴

Given that antibiotic resistance is one of the most pressing public health threats globally, a simple test that helps clinicians say “no” with confidence is a genuinely valuable tool. A systematic review of cost-effectiveness studies found that most point-of-care strategies that reduced antimicrobial prescribing were cost-effective at modest willingness-to-pay thresholds, and the majority either improved or had no negative effect on clinical outcomes.

¹⁵

Global Health and Low-Resource Settings

The places where point-of-care testing arguably matters most are the ones least likely to have a functioning central laboratory. Malaria rapid diagnostic tests are among the most widely deployed point-of-care devices in the world, used across sub-Saharan Africa in settings ranging from health posts to community health worker kits. These tests are inexpensive, require no electricity, and give results in 15 to 20 minutes. A meta-analysis of their performance in African endemic regions found pooled sensitivity of about 83% and specificity of about 95%.

¹⁶

That specificity is strong, meaning false positives are rare, but the 83% sensitivity means roughly one in six true malaria cases could be missed. In high-transmission areas where the consequences of a missed case are severe, that gap matters, and expert microscopy or molecular testing remains important as backup when available.

Even so, rapid diagnostic tests have transformed malaria management in resource-limited settings precisely because they are cheap and easy to use.

¹⁷

Before their widespread rollout, many febrile patients in Africa were treated presumptively for malaria regardless of whether they actually had it, driving drug resistance and missing other causes of fever.

A practical challenge in tropical settings, however, is that heat and humidity can degrade point-of-care devices. A study found that even 15 minutes of exposure to high temperature and humidity produced errors as large as 30% in point-of-care glucose readings, with stressed meters and test strips both contributing to elevated results.

¹⁸

Other work has confirmed that high temperature and humidity can shift glucose readings in the opposite direction depending on the chemistry used, with oxidase-based systems showing decreased readings under tropical conditions.

¹⁹

This means the same device can be reliable in an air-conditioned hospital and unreliable under a corrugated metal roof, a reality that storage guidelines and cold-chain logistics need to account for.

How Accurate Are They Compared to the Lab

The trade-off between speed and accuracy is the question that follows every conversation about point-of-care testing. The answer depends heavily on what you are measuring. A study comparing a point-of-care blood gas analyzer against central laboratory instruments in critically ill patients found that the device met accepted interchangeability standards for glucose, electrolytes, bicarbonate, and hematocrit, but not for hemoglobin. The researchers concluded that clinicians could reasonably start treatment based on the point-of-care results without waiting for laboratory confirmation.

²⁰

In newborns, where the stakes of small measurement errors are higher and blood volumes are tiny, a neonatal ICU study found that glucose and hemoglobin measurements from point-of-care devices tracked closely with central lab values, but sodium and chloride showed larger discrepancies.

²¹

The pattern across studies is consistent: point-of-care devices tend to do well with glucose, blood gases, and some hematology parameters, but struggle more with electrolytes and certain proteins. Any hospital deploying these devices needs to validate them against their own central laboratory for the specific analytes and patient populations they intend to cover.

A simulation analysis reinforced this nuance by examining the overall impact on patient outcomes. In rural and community settings, where transporting samples to a central lab introduces hours of delay, the speed advantage of point-of-care testing more than compensated for its slightly lower test quality, resulting in fewer total lost productive hours per patient. In hospital-based settings, where the lab is in the same building, the quality advantage of central laboratory testing largely offset the faster turnaround of point-of-care devices, making the two approaches roughly equivalent.

²²

The Economics of Testing at the Bedside

Point-of-care testing creates a genuine economic tension. Individual test costs are higher than central lab tests because you lose the economies of scale that come with high-volume automated analyzers processing hundreds of samples an hour. Reagent cartridges for bedside devices cost more per unit, quality-control procedures need to be duplicated at every testing location, and training requirements expand beyond laboratory staff to nurses, respiratory therapists, and sometimes patients themselves.

²³

But the savings show up elsewhere in the system. Shorter emergency department stays reduce facility costs and free up beds. Earlier antibiotic delivery in sepsis may prevent ICU admissions. Fewer unnecessary antibiotic prescriptions reduce downstream costs of resistant infections. When health economic evaluations are taken together, over 75% of published analyses have concluded that point-of-care testing is worth implementing, though often with caveats about specific conditions and settings.

²⁴

Environmental Costs of Disposable Devices

An issue that rarely comes up in clinical discussions is what happens to all these devices after use. Point-of-care tests are overwhelmingly single-use. Lateral flow strips, cartridges, and microfluidic chips are typically made from petroleum-derived polymers and often contain chemicals that require careful disposal. Because they contact biological samples, many need to be incinerated, releasing additional carbon dioxide. A growing body of work has flagged this as a sustainability concern, noting that some devices contain toxic compounds like cyanide derivatives that pose environmental and health risks if improperly discarded.

²⁵

The COVID-19 pandemic, which generated billions of rapid antigen tests worldwide, brought this issue into sharp relief. Research into biodegradable substrates and recyclable device architectures is underway but has not yet produced widely adopted commercial alternatives.

Where the Technology Is Heading

The next generation of point-of-care devices is being shaped by two converging trends: microfluidics and machine learning. Microfluidic platforms, sometimes called lab-on-a-chip systems, miniaturize the sample-processing steps that currently require laboratory benchtops. Some integrate DNA extraction, amplification, and detection on a single disposable disc, reaching diagnostic accuracy comparable to standard laboratory molecular tests.

²⁶

Saliva-based microfluidic devices are pushing toward truly non-invasive testing, detecting biomarkers without a blood draw at all.

²⁷

Machine learning is being layered onto biosensor platforms to improve interpretation of complex signals. Rather than relying on a simple threshold (“line appears or it doesn’t”), algorithms trained on large datasets can extract quantitative information from noisy sensor outputs, improving sensitivity and reducing the skill needed from the person running the test.

²⁸

One team has already demonstrated a nucleic-acid-based device for infectious disease detection that pairs a low-cost portable reader with a smartphone app running machine-learning-powered colorimetric analysis, designed specifically for settings where laboratory infrastructure is sparse.

²⁹

Beyond Human Medicine

Point-of-care diagnostics are not limited to human patients. Veterinary medicine has adopted rapid tests for diseases with major economic and public health consequences: foot-and-mouth disease, avian influenza, rabies, and African swine fever, among others. Field studies in eastern Africa using a portable molecular assay for foot-and-mouth disease achieved diagnostic accuracy comparable to standard laboratory methods, a meaningful result when the nearest veterinary lab may be a day’s travel away.

³⁰

For zoonotic diseases that jump between animals and humans, catching an outbreak in livestock before it spreads to the human population is one of the most cost-effective public health interventions that exists, and rapid field-deployable tests are what make that surveillance feasible in the places where it is needed most.